Genmab A/S (NASDAQ:GMAB) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the stock.

A number of other research analysts have also recently commented on GMAB. BTIG Research upped their price target on Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Royal Bank of Canada upgraded shares of Genmab A/S from a sector perform rating to an outperform rating in a research note on Monday, July 15th. Truist Financial reduced their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a buy rating on the stock in a report on Monday, September 9th. Morgan Stanley reiterated an equal weight rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and an average price target of $45.20.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $24.14 on Friday. Genmab A/S has a one year low of $24.05 and a one year high of $36.71. The stock has a 50 day moving average price of $27.22 and a 200 day moving average price of $27.94. The stock has a market cap of $15.96 billion, a PE ratio of 20.12, a P/E/G ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. As a group, analysts predict that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC purchased a new position in Genmab A/S in the 2nd quarter valued at $1,354,000. Point72 Asset Management L.P. purchased a new stake in Genmab A/S in the 2nd quarter valued at approximately $457,000. Cubist Systematic Strategies LLC raised its stake in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.